Trade Aytu BioScience, Inc. - AYTU CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Trading Conditions
| Spread | 0.114 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.025457% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003235% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.01 | ||||||||
| Currency | USD | ||||||||
| Margin | 20% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Aytu Biopharma Inc ESG Risk Ratings
High Medium Low Negligible
‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.
Key Stats
| Prev. Close* | 1.687 |
| Open* | 1.647 |
| 1-Year Change* | 206.7% |
| Day's Range* | 1.568 - 1.647 |
| 52 wk Range | 1.40-16.19 |
| Average Volume (10 days) | 49.71K |
| Average Volume (3 months) | 1.67M |
| Market Cap | 6.62M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 3.78M |
| Revenue | 104.12M |
| EPS | -206.58 |
| Dividend (Yield %) | N/A |
| Beta | -0.37 |
| Next Earnings Date | Sep 25, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jun 6, 2023 | 1.568 | -0.078 | -4.74% | 1.646 | 1.648 | 1.568 |
| Jun 5, 2023 | 1.687 | -0.039 | -2.26% | 1.726 | 1.726 | 1.637 |
| Jun 2, 2023 | 1.736 | 0.139 | 8.70% | 1.597 | 1.736 | 1.587 |
| Jun 1, 2023 | 1.647 | 0.060 | 3.78% | 1.587 | 1.667 | 1.568 |
| May 31, 2023 | 1.618 | -0.038 | -2.29% | 1.656 | 1.657 | 1.568 |
| May 30, 2023 | 1.618 | -0.078 | -4.60% | 1.696 | 1.697 | 1.587 |
| May 26, 2023 | 1.627 | 0.000 | 0.00% | 1.627 | 1.805 | 1.617 |
| May 25, 2023 | 1.618 | -0.147 | -8.33% | 1.765 | 1.766 | 1.558 |
| May 24, 2023 | 1.746 | -0.029 | -1.63% | 1.775 | 1.815 | 1.696 |
| May 23, 2023 | 1.765 | -0.009 | -0.51% | 1.774 | 1.904 | 1.765 |
| May 22, 2023 | 1.874 | 0.020 | 1.08% | 1.854 | 1.934 | 1.824 |
| May 19, 2023 | 1.844 | 0.020 | 1.10% | 1.824 | 1.934 | 1.795 |
| May 18, 2023 | 1.835 | 0.020 | 1.10% | 1.815 | 1.854 | 1.775 |
| May 17, 2023 | 1.736 | 0.090 | 5.47% | 1.646 | 1.746 | 1.607 |
| May 16, 2023 | 1.677 | 0.001 | 0.06% | 1.676 | 1.795 | 1.666 |
| May 15, 2023 | 1.726 | 0.011 | 0.64% | 1.715 | 1.805 | 1.697 |
| May 12, 2023 | 1.776 | -0.246 | -12.17% | 2.022 | 2.022 | 1.726 |
| May 11, 2023 | 2.022 | -0.010 | -0.49% | 2.032 | 2.151 | 1.913 |
| May 10, 2023 | 2.002 | 0.060 | 3.09% | 1.942 | 2.092 | 1.804 |
| May 9, 2023 | 1.953 | 0.326 | 20.04% | 1.627 | 2.052 | 1.577 |
Aytu BioScience, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Monday, September 25, 2023 | ||
| Time (UTC) 20:00 | Country US
| Event Q4 2023 Aytu Biopharma Inc Earnings Release Q4 2023 Aytu Biopharma Inc Earnings ReleaseForecast -Previous - |
| Monday, November 13, 2023 | ||
| Time (UTC) 21:00 | Country US
| Event Q1 2024 Aytu Biopharma Inc Earnings Release Q1 2024 Aytu Biopharma Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 96.669 | 65.632 | 27.6321 | 7.32036 | 3.66012 |
| Revenue | 96.669 | 65.632 | 27.6321 | 7.32036 | 3.66012 |
| Cost of Revenue, Total | 44.386 | 36.432 | 7.55303 | 2.20204 | 2.05054 |
| Gross Profit | 52.283 | 29.2 | 20.0791 | 5.11832 | 1.60958 |
| Total Operating Expense | 208.061 | 126.071 | 38.6481 | 33.9975 | 17.0825 |
| Selling/General/Admin. Expenses, Total | 69.88 | 55.808 | 34.8024 | 19.2396 | 17.7325 |
| Research & Development | 14.439 | 5.623 | 1.72142 | 0.58907 | 0.1676 |
| Depreciation / Amortization | 4.067 | 6.009 | 4.49047 | 2.13626 | 1.55371 |
| Unusual Expense (Income) | 75.289 | 22.199 | -9.91925 | 9.83055 | -4.42185 |
| Operating Income | -111.392 | -60.439 | -11.016 | -26.6772 | -13.4224 |
| Interest Income (Expense), Net Non-Operating | -0.862 | -2.05 | -2.60466 | -0.45472 | 3.2345 |
| Net Income Before Taxes | -110.283 | -58.03 | -13.6207 | -27.1319 | -10.1879 |
| Net Income After Taxes | -110.173 | -58.289 | -13.6207 | -27.1319 | -10.1879 |
| Net Income Before Extra. Items | -110.173 | -58.289 | -13.6207 | -27.1319 | -10.1879 |
| Net Income | -110.173 | -58.289 | -13.6207 | -27.1319 | -10.1879 |
| Income Available to Common Excl. Extra. Items | -110.173 | -58.289 | -13.6207 | -27.1319 | -10.1879 |
| Income Available to Common Incl. Extra. Items | -110.173 | -58.289 | -13.6207 | -27.1319 | -10.1879 |
| Diluted Net Income | -110.173 | -58.289 | -13.6207 | -27.1319 | -10.1879 |
| Diluted Weighted Average Shares | 0.07349 | 0.83733 | 0.22596 | 0.03897 | 0.00333 |
| Diluted EPS Excluding Extraordinary Items | -1499.08 | -69.6126 | -60.2791 | -696.182 | -3061.23 |
| Dividends per Share - Common Stock Primary Issue | |||||
| Diluted Normalized EPS | -833.202 | -52.3801 | -104.177 | -443.938 | -4389.91 |
| Total Extraordinary Items | 0 | ||||
| Other, Net | 1.971 | 4.459 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total revenue | 22.733 | 26.279 | 27.655 | 27.448 | 24.199 |
| Revenue | 22.733 | 26.279 | 27.655 | 27.448 | 24.199 |
| Cost of Revenue, Total | 9.99 | 8.986 | 9.623 | 12.606 | 11.513 |
| Gross Profit | 12.743 | 17.293 | 18.032 | 14.842 | 12.686 |
| Total Operating Expense | 31.291 | 33.072 | 29.308 | 45.361 | 78.685 |
| Selling/General/Admin. Expenses, Total | 19.981 | 18.578 | 17.424 | 17.396 | 17.358 |
| Research & Development | 0.856 | 1.71 | 1.064 | 3.697 | 3.726 |
| Depreciation / Amortization | 1.198 | 1.198 | 1.197 | 0.853 | 1.061 |
| Unusual Expense (Income) | 0 | 2.6 | 10.809 | 45.027 | |
| Operating Income | -8.558 | -6.793 | -1.653 | -17.913 | -54.486 |
| Interest Income (Expense), Net Non-Operating | 1.358 | 0.1 | 1.08 | -0.787 | -0.055 |
| Other, Net | -0.128 | 0.999 | 1.468 | ||
| Net Income Before Taxes | -7.2 | -6.693 | -0.701 | -17.701 | -53.073 |
| Net Income After Taxes | -7.2 | -6.693 | -0.701 | -17.701 | -53.073 |
| Net Income Before Extra. Items | -7.2 | -6.693 | -0.701 | -17.701 | -53.073 |
| Net Income | -7.2 | -6.693 | -0.701 | -17.701 | -53.073 |
| Income Available to Common Excl. Extra. Items | -7.2 | -6.693 | -0.701 | -17.701 | -53.073 |
| Income Available to Common Incl. Extra. Items | -7.2 | -6.693 | -0.701 | -17.701 | -53.073 |
| Diluted Net Income | -7.2 | -6.693 | -0.701 | -17.701 | -53.073 |
| Diluted Weighted Average Shares | 3.72678 | 3.1103 | 0.1259 | 0.08989 | 1.48449 |
| Diluted EPS Excluding Extraordinary Items | -1.93196 | -2.15188 | -5.56812 | -196.925 | -35.7516 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -1.93196 | -1.31595 | -5.56812 | -76.6739 | -5.42003 |
| Other Operating Expenses, Total | -0.734 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 59.929 | 105.234 | 75.4226 | 15.4329 | 9.47029 |
| Cash and Short Term Investments | 19.36 | 49.649 | 48.0817 | 11.0442 | 7.01253 |
| Cash & Equivalents | 19.36 | 49.649 | 48.0817 | 11.0442 | 7.01253 |
| Short Term Investments | |||||
| Total Receivables, Net | 21.712 | 28.176 | 5.63272 | 1.74079 | 0.57878 |
| Accounts Receivable - Trade, Net | 21.712 | 28.176 | 5.63272 | 1.74079 | 0.57878 |
| Total Inventory | 10.849 | 16.339 | 9.99944 | 1.44007 | 1.33897 |
| Prepaid Expenses | 7.375 | 9.78 | 5.71509 | 0.95778 | 0.44001 |
| Total Assets | 137.623 | 265.668 | 153.293 | 34.7214 | 21.0601 |
| Property/Plant/Equipment, Total - Net | 6.296 | 8.703 | 0.89261 | 0.20373 | 0.21868 |
| Goodwill, Net | 0 | 65.802 | 28.0904 | 0 | |
| Intangibles, Net | 70.632 | 85.464 | 48.8546 | 19.0826 | 11.366 |
| Other Long Term Assets, Total | 0.766 | 0.465 | 0.03298 | 0.0022 | 0.00509 |
| Total Current Liabilities | 64.442 | 109.438 | 28.7634 | 5.37258 | 3.39478 |
| Payable/Accrued | 9.468 | 8.689 | 0.959 | ||
| Accrued Expenses | 35.946 | 49.485 | 11.1046 | 1.99724 | 0.72656 |
| Notes Payable/Short Term Debt | 3.813 | 7.934 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 4.132 | 7.407 | 4.87523 | 1.07807 | 0.54855 |
| Total Liabilities | 91.531 | 128.1 | 58.2778 | 27.6336 | 7.63559 |
| Total Long Term Debt | 14.279 | 0.18 | 0 | 0 | 0 |
| Other Liabilities, Total | 12.81 | 18.482 | 29.5145 | 22.261 | 4.24081 |
| Total Equity | 46.092 | 137.568 | 95.0153 | 7.08782 | 13.4245 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0.00036 | 0 |
| Common Stock | 0.004 | 0.003 | 0.00126 | 0.00175 | 0.00018 |
| Additional Paid-In Capital | 334.56 | 315.864 | 215.024 | 113.475 | 92.6819 |
| Retained Earnings (Accumulated Deficit) | -288.472 | -178.299 | -120.01 | -106.39 | -79.2576 |
| Total Liabilities & Shareholders’ Equity | 137.623 | 265.668 | 153.293 | 34.7214 | 21.0601 |
| Total Common Shares Outstanding | 1.92894 | 1.37452 | 0.62919 | 0.08769 | 0.00897 |
| Other Current Assets, Total | 0.633 | 1.29 | 5.9936 | 0.25 | 0.1 |
| Accounts Payable | 10.987 | 19.255 | 11.8246 | 2.29727 | 2.11967 |
| Property/Plant/Equipment, Total - Gross | 8.717 | 9.715 | 1.37661 | 0.59973 | 0.75868 |
| Accumulated Depreciation, Total | -2.421 | -1.012 | -0.484 | -0.396 | -0.54 |
| Total Preferred Shares Outstanding | 0 | 0 | 3.59498 | ||
| Current Port. of LT Debt/Capital Leases | 0.096 | 16.668 | 0 | ||
| Capital Lease Obligations | 0.084 | 0.18 | 0 | ||
| Long Term Debt | 14.195 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 78.465 | 70.611 | 74.415 | 59.929 | 77.947 |
| Cash and Short Term Investments | 19.179 | 19.501 | 23.811 | 19.36 | 27.613 |
| Cash & Equivalents | 19.179 | 19.501 | 23.811 | 19.36 | 27.613 |
| Total Receivables, Net | 34.043 | 25.547 | 27.924 | 21.712 | 27.613 |
| Accounts Receivable - Trade, Net | 34.043 | 25.547 | 27.924 | 21.712 | 27.613 |
| Total Inventory | 13.637 | 12.95 | 12.871 | 10.849 | 13.891 |
| Prepaid Expenses | 10.429 | 11.989 | 9.024 | 7.375 | 7.942 |
| Other Current Assets, Total | 1.177 | 0.624 | 0.785 | 0.633 | 0.888 |
| Total Assets | 147.216 | 141.436 | 150 | 137.623 | 168.826 |
| Property/Plant/Equipment, Total - Net | 4.395 | 5.019 | 5.648 | 6.296 | 7.04 |
| Property/Plant/Equipment, Total - Gross | 7.779 | 8.083 | 8.384 | 8.717 | 8.78 |
| Accumulated Depreciation, Total | -3.384 | -3.064 | -2.736 | -2.421 | -1.74 |
| Goodwill, Net | 0 | 8.637 | |||
| Intangibles, Net | 63.464 | 64.985 | 69.108 | 70.632 | 74.428 |
| Other Long Term Assets, Total | 0.892 | 0.821 | 0.829 | 0.766 | 0.774 |
| Total Current Liabilities | 85.416 | 67.15 | 73.204 | 64.442 | 80.36 |
| Accounts Payable | 14.673 | 10.58 | 14.667 | 10.987 | 11.13 |
| Payable/Accrued | 10.287 | 9.137 | 8.08 | 9.468 | 12.058 |
| Accrued Expenses | 40.55 | 33.326 | 34.603 | 35.946 | 47.873 |
| Notes Payable/Short Term Debt | 10.403 | 7.429 | 8.087 | 3.813 | 3.385 |
| Current Port. of LT Debt/Capital Leases | 3.305 | 0.09 | 0.925 | 0.096 | 0.1 |
| Other Current Liabilities, Total | 6.198 | 6.588 | 6.842 | 4.132 | 5.814 |
| Total Liabilities | 106.304 | 95.619 | 96.094 | 91.531 | 107.682 |
| Total Long Term Debt | 11.386 | 14.533 | 13.56 | 14.279 | 14.167 |
| Long Term Debt | 11.371 | 14.494 | 13.498 | 14.195 | 14.061 |
| Capital Lease Obligations | 0.015 | 0.039 | 0.062 | 0.084 | 0.106 |
| Other Liabilities, Total | 9.502 | 13.936 | 9.33 | 12.81 | 13.155 |
| Total Equity | 40.912 | 45.817 | 53.906 | 46.092 | 61.144 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.00038 | 0.00034 | 0.006 | 0.004 | 0.003 |
| Additional Paid-In Capital | 342.584 | 340.289 | 345.253 | 334.56 | 331.912 |
| Retained Earnings (Accumulated Deficit) | -301.672 | -294.472 | -291.353 | -288.472 | -270.771 |
| Total Liabilities & Shareholders’ Equity | 147.216 | 141.436 | 150 | 137.623 | 168.826 |
| Total Common Shares Outstanding | 3.77951 | 3.38315 | 3.12147 | 1.92894 | 1.6678 |
| Total Preferred Shares Outstanding | |||||
| Other Equity, Total | -0.00038 | -0.00034 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -110.173 | -58.289 | -13.6207 | -27.1319 | -10.1879 |
| Cash From Operating Activities | -28.823 | -25.964 | -28.3739 | -13.8314 | -15.9403 |
| Cash From Operating Activities | 10.251 | 9.201 | 6.24583 | 2.72707 | 2.59127 |
| Deferred Taxes | |||||
| Non-Cash Items | 81.962 | 21.443 | -8.38913 | 10.7837 | -7.62492 |
| Changes in Working Capital | -10.863 | 1.681 | -12.6099 | -0.2102 | -0.71881 |
| Cash From Investing Activities | -3.248 | -2.782 | -5.65577 | -1.06199 | -0.48429 |
| Capital Expenditures | -2.341 | 0 | -0.05985 | -0.07471 | |
| Other Investing Cash Flow Items, Total | -3.248 | -0.441 | -5.65577 | -1.00214 | -0.40959 |
| Cash From Financing Activities | 1.53 | 30.314 | 71.0687 | 19.0751 | 22.6596 |
| Financing Cash Flow Items | -4.942 | -10.996 | -5.40415 | -1.47996 | -2.75752 |
| Issuance (Retirement) of Stock, Net | 11.694 | 45.051 | 92.7217 | 15.555 | 25.4171 |
| Issuance (Retirement) of Debt, Net | -5.222 | -3.741 | -16.2488 | 5 | |
| Net Change in Cash | -30.541 | 1.568 | 37.0391 | 4.1817 | 6.23499 |
| Cash Interest Paid | 3.148 | 1.249 | 1.04028 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -14.594 | -7.394 | -2.881 | -110.173 | -92.472 |
| Cash From Operating Activities | -14.494 | -11.588 | -9.148 | -28.823 | -21.728 |
| Cash From Operating Activities | 6.699 | 4.505 | 2.328 | 10.251 | 8.005 |
| Non-Cash Items | 1.658 | 3.846 | 1.488 | 81.962 | 67.39 |
| Cash Interest Paid | 2.861 | 2.021 | 0.565 | 3.148 | 3.08 |
| Changes in Working Capital | -8.257 | -12.545 | -10.083 | -10.863 | -4.651 |
| Cash From Investing Activities | 0.038 | 0.037 | 0.042 | -3.248 | -3.207 |
| Other Investing Cash Flow Items, Total | 0.038 | 0.037 | 0.042 | -3.248 | -3.207 |
| Cash From Financing Activities | 14.275 | 11.692 | 13.557 | 1.53 | 2.647 |
| Financing Cash Flow Items | -5.254 | -3.497 | -1.107 | -4.942 | -4.429 |
| Issuance (Retirement) of Stock, Net | 13.012 | 11.573 | 10.416 | 11.694 | 12.7 |
| Issuance (Retirement) of Debt, Net | 6.517 | 3.616 | 4.248 | -5.222 | -5.624 |
| Net Change in Cash | -0.181 | 0.141 | 4.451 | -30.541 | -22.288 |
| Capital Expenditures |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| Nantahala Capital Management, LLC | Hedge Fund | 7.1847 | 271595 | 0 | 2023-05-26 | LOW |
| Alyeska Investment Group, L.P. | Hedge Fund | 1.984 | 75000 | 0 | 2023-03-31 | |
| Brooke (Christopher) | Individual Investor | 1.5438 | 58357 | 58357 | 2022-11-15 | |
| Disbrow (Joshua R.) | Individual Investor | 1.5235 | 57591 | -3 | 2023-03-24 | LOW |
| Renaissance Technologies LLC | Hedge Fund | 1.3127 | 49623 | -57416 | 2023-03-31 | HIGH |
| Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 1.2503 | 47263 | 4379 | 2023-03-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.6365 | 24059 | -1 | 2023-03-31 | LOW |
| Acadian Asset Management LLC | Investment Advisor/Hedge Fund | 0.5962 | 22537 | 2640 | 2023-03-31 | MED |
| Commonwealth Financial Network | Investment Advisor | 0.4137 | 15637 | 159 | 2023-03-31 | LOW |
| PGIM Quantitative Solutions LLC | Investment Advisor | 0.375 | 14176 | 5198 | 2023-03-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.3185 | 12039 | -2 | 2023-03-31 | LOW |
| Oki (Mark K) | Individual Investor | 0.2513 | 9500 | 0 | 2023-03-24 | LOW |
| Pyszczymuka (Greg) | Individual Investor | 0.2408 | 9103 | 5000 | 2022-12-19 | |
| Cantrell (Gary V.) | Individual Investor | 0.217 | 8204 | -2000 | 2022-12-21 | |
| Dockery (Carl C) | Individual Investor | 0.2157 | 8152 | -2 | 2023-03-24 | LOW |
| Liu (Vivian H) | Individual Investor | 0.1805 | 6825 | 0 | 2023-03-24 | HIGH |
| Ronald Blue Trust, Inc. | Investment Advisor | 0.1476 | 5579 | 5300 | 2023-03-31 | LOW |
| UBS Financial Services, Inc. | Investment Advisor | 0.1395 | 5273 | 5012 | 2023-03-31 | LOW |
| Tower Research Capital LLC | Hedge Fund | 0.0457 | 1726 | 113 | 2023-03-31 | HIGH |
| Morgan Stanley & Co. LLC | Research Firm | 0.0228 | 861 | 0 | 2023-03-31 | MED |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Trade commission
0
- 1:1
Leverage
1:1
- 20
- 100
- 500
- 1000
- 10000
Investment
Trade size (Leverage x Investement):
Open
Close
Short Long
Aytu BioScience, Inc. Company profile
About Aytu Biopharma Inc
Aytu Biopharma, Inc., formerly Aytu BioScience, Inc., is a specialty pharmaceutical company. The Company markets a portfolio of prescription products addressing primary care and pediatric markets. The Company's primary prescription products treat attention deficit hyperactivity disorder (ADHD) and other common pediatric conditions. It markets ADHD products Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets, Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets, and Adzenys-ER (amphetamine) extended-release oral suspension. The Company's other pediatric products include Karbinal ER (carbinoxamine maleate), an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary fluoride-based prescription vitamin product lines containing combinations of fluoride and vitamins in formulations for infants and children with fluoride deficiency.
Financial summary
BRIEF: For the six months ended 31 December 2021, Aytu Biopharma Inc revenues increased 57% to $45M. Net loss increased from $13.8M to $39.4M. Revenues reflect United States segment increase of 69% to $43.7M. Basic Earnings per Share excluding Extraordinary Items decreased from -$1.07 to -$1.53.
Equity composition
Common Stock no Par, 11/11, 30M auth., 4,774,568 issd. Insiders own 66.98%. 06/15, 1-for-12.174, Reverse Stock Split.
| Industry: | Pharmaceuticals (NEC) |
373 Inverness Pkwy Ste 206
80112
Income Statement
- Annual
- Quarterly
News
USD/TRY forecast: Turkish lira under pressure from high inflation and low rates
We look at some of the latest USD/TRY predictions as the Turkish lira hits record lows.
17:07, 1 June 2023
Nvidia’s 5-year stock forecast: Will the chipmaker remain at record highs?
Nvidia has been the winner of the AI race, being the first chip-maker to hit a $1tn market cap. Will the growth continue?
07:46, 31 May 2023
Google stock forecast 2023-2025
What is the outlook for the tech giant, following a tumultuous 2022?
18:02, 30 May 2023
USD forecast: DXY slides in risk-off market sentiment
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
16:10, 24 May 2023
Oil price forecast: Will WTI and Brent regain momentum in 2023?
Discover the drivers behind Brent and WTI volatility and get insights from analyst predictions.
11:38, 22 May 2023
Weekly Roundup: Tech stocks lead the way
US stocks push higher as risk appetite surges despite the uncertainty
13:39, 19 May 2023
USD/JPY continues to build higher towards 138
USD/JPY advances towards the top of its ascending triangle as the US dollar moves higher
11:50, 17 May 2023People also watch
Still looking for a broker you can trust?
Join the 535.000+ traders worldwide that chose to trade with Capital.com